SPIKEVAX JN.1 ser pré 10 x 0.5 ml

7680697880029 CH-69788 J07BX 08.08.

Reimbursement limitations:

0808 NEU

La prise en charge des coûts des vaccins au titre de mesure préventive dans le …

SPIKEVAX JN.1 ser pré 10 x 0.5 ml
SPIKEVAX JN.1 ser pré 10 x 0.5 ml
SPIKEVAX JN.1 ser pré 10 x 0.5 ml
1 / 3
google

Details

Product number
6978801
CPT
-
Packaging group
10
Unit
Fertigspritze(n)
Composition
Suspension: SARS-CoV-2 JN.1 mRNA 50 µg pro dosi, heptadecan-9-ylis 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)-octanoas, cholesterolum, 1,2-distearoyl-sn-glycero-3-phosphocholinum, 1,2-dimyristoyl-rac-glycero-3-polyethylenglycoli 2000 aether methylicus, trometamolum, trometamoli hydrochloridum, acidum aceticum, natrii acetas trihydricus, saccharum, aqua ad iniectabile, pro dosi, natrium 0.017 mg pro dosi.

Articles (1)

Spikevax JN.1 (mRNA-1273.167), 0.10mg/ml, Dispersion zur Injektion
0.10mg/ml, Dispersion zur Injektion
10
View

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
11/07/2025
Patient information leaflet
Français
11/07/2025
Patient information leaflet
Italien
11/07/2025
Professional SmPC
Allemand
11/07/2025
Professional SmPC
Français
11/07/2025
Professional SmPC
Italien
11/07/2025

Detailed composition

Substance Quantity Type Category
SUS
50.0 UG Substance Wirkstoff (Principe actif)
SUS
- Substance HNIDK
SUS
- Substance HNIDK
SUS
- Substance HNIDK
SUS
- Substance HNIDK
SUS
- Substance HNIDK
SUS
- Substance HNIDK
SUS
- Substance HNIDK
SUS
- Substance HNIDK
SUS
- Substance HNIDK
SUS
- Substance HNIDK
SUS
0.017 MG Substance HBESI

Authorization holder

Moderna Switzerland GmbH

4052 Basel

Authorization information

Swissmedic authorization number
69788
Drug name
Spikevax JN.1 (mRNA-1273.167), Dispersion zur Injektion
Galenic form
DISIJ
ATC Code
J07BX
Authorization status
Z
Dispensation category
B
First authorization
09/09/2024
Authorization expiration date
08/09/2029
IT number
08.08.
Domain
Human medicine
Field of application
Spikevax JN.1 ist für die aktive Immunisierung zur Vorbeugung der durch das SARS-CoV-2-Virus verursachten Coronavirus-2019-Erkrankung (COVID-19) bei Personen ab 12 Jahren indiziert

Packaging details

Description (FR)
SPIKEVAX JN.1 ser pré 10 x 0.5 ml
Description (DE)
SPIKEVAX JN.1 Fertspr 10 x 0.5 ml
Market launch
09/09/2024
Market withdrawal
02/09/2025
Narcotic (BTM)
No

Other packaging sizes

SPIKEVAX JN.1 ser pré 0.5 ml
1 FESP
GTIN: 7680697880012
View